Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review | Zendy

Tim Hropot | Zendy; Tadej Battelino | Zendy; Klemen Dovč | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Author(s) -

Tim Hropot,

Tadej Battelino,

Klemen Dovč

Publication year - 2022

Publication title -

hormone research in paediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.816

H-Index - 89

eISSN - 1663-2826

pISSN - 1663-2818

DOI - 10.1159/000527653

Subject(s) - type 2 diabetes , medicine , renal glucose reabsorption , diabetes mellitus , insulin , clinical trial , endocrinology , placebo , pharmacology , alternative medicine , pathology

With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are glucose-lowering agents that inhibit the reabsorption of filtered glucose in the kidneys, thus promoting glucosuria. Because the glucose-lowering effect of SGLT2 inhibitors is achieved independently of insulin secretion, it has been speculated whether they could bridge the gap towards achieving glycaemic targets in individuals with type 1 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research